Clinical trials: Paralysis; Eye
Progressive Supranuclear Palsy, Dementia
Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy
to show that 1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function 2. use of rivastigmine has a positive effect on apathy in PSP patients 3.
- Trial name
- psp (NCT00522015)
- Testing
- rivastigmine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Blepharoptosis, Device Usability
A Feedback-enabled Magnetic Device for Temporary Management of Blepharoptosis
To develop a feedback-enabled magnetic device for management of blepharoptosis and evaluate its efficacy and safety, including the gain of palpebral fissure height, visual field obstruction, blurred vision, foreign body sensation…
- Trial name
- NCT03812016
- Testing
- Feedback-enabled magnetic device
- Where
- 2 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- E-DA Hospital
Stroke, CVA (Cerebrovascular Accident)
MORbidity PRevalence Estimate In StrokE
Information regarding the likely progress of post-stroke symptoms is vitally important to stroke survivors to allow them to plan for the future and to adjust to life after stroke.
- Conditions
- Stroke, CVA (Cerebrovascular Accident), CVA; Sequelae, Stroke, Ischemic
- Trial name
- MORe PREcISE (NCT03605381)
- Where
- 3 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Aneurin Bevan University Health Board
Progressive Supranuclear Palsy (PSP)
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT03391765
- Testing
- ABBV-8E12
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 142 people
- Sponsor
- AbbVie
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
- Trial name
- NCT07868328
- Testing
- NIO752
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
PSP, CBD
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
The primary objective of this study is to enroll an observational cohort of approximately 60 patients with PSP over the course of 24 months using a multicenter study design and to follow each of them for 12 months.
- Conditions
- PSP, CBD, Progressive Supranuclear Palsy, FTD
- Trial name
- NCT05956834
- Testing
- PAMSys, LEGSys
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Cerebral Palsy
Optic Discs in Children With Cerebral Palsy
Hypothesis: Children born prematurely (between 8 and 9 months) with brain damage have an abnormal appearance of the optic nerve (nerve in eye) that resembles glaucoma (cupping) compared to those born before 8 months.
- Trial name
- NCT00769197
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Mississippi Medical Center
Progressive Supranuclear Palsy
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
The purpose of this study is to evaluate the safety and tolerability of multiple ascending intravenous infusions of BMS-986168 and to assess the pharmacokinetics and immunogenicity of BIIB092, and pharmacodynamics of BIIB092 on…
- Trial name
- CN002-003 (NCT02460094)
- Testing
- BIIB092
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- Biogen
Mitochondrial Diseases, Kearns-Sayre Syndrome
Global Registry and Natural History Study for Mitochondrial Disorders
The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and facilitate natural history studies, definition of outcome…
- Conditions
- Mitochondrial Diseases, Kearns-Sayre Syndrome, MIDD, SANDO
- Trial name
- GENOMIT (NCT05554835)
- Where
- 34 sites in Austria, Germany and 1 more
- Volunteers
- 6,000 people
- Sponsor
- LMU Klinikum
Parkinson Disease, Parkinsonism
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
The purpose of this study is to determine whether identification of misfolded proteins in the skin will help to determine what sort of parkinsonism someone has.
- Conditions
- Parkinson Disease, Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy
- Trial name
- NCT04518059
- Testing
- punch skin biopsy
- Where
- 2 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Progressive Supranuclear Palsy
Art Therapy in Progressive Supranuclear Palsy
Our aim is to study the effect of art therapy for people with PSP, with a focus on alleviating the symptoms associated with PSP, enhancing the overall quality of life for patients, and reducing caregiver stress.
- Trial name
- NCT06588673
- Testing
- Art Thrapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Vanderbilt University Medical Center
Parkinson Disease, Multiple System Atrophy
Diagnostic and Prognostic Biomarkers in Parkinson Disease
The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- PROBE (NCT00653783)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Parkinson Study Group
Eye Diseases Hereditary, Retinal Disease
Inherited Retinal Degenerative Disease Registry
The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation.
- Conditions
- Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome
- Trial name
- MRTR (NCT02435940)
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Foundation Fighting Blindness
Supranuclear Palsy, Progressive
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of…
- Trial name
- PASSPORT (NCT03068468)
- Testing
- BIIB092
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 490 people
- Sponsor
- Biogen
Parkinson Disease, Essential Tremor
Brain Network Activation in Patients With Movement Disorders
The diagnosis and management of movement disorders, such as Parkinson's disease (PD), parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure hydrocephalus (NPH) and others is challenging given the lack…
- Conditions
- Parkinson Disease, Essential Tremor, Dystonia, Normal Pressure Hydrocephalus
- Trial name
- BNA-MDi (NCT03269201)
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Sheba Medical Center
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration
PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Progressive Supranuclear Palsy (PSP), Cortico-Basal Degeneration (CBD) and Multiple System Atrophy (MSA) are degenerative brain conditions for which there are currently no curative treatments.
- Conditions
- Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration, Multiple System Atrophy (MSA)
- Trial name
- PROSPECT-M (NCT02778607)
- Where
- United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University College, London
Progressive Supranuclear Palsy
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
The study will be conducted by the Sponsor to evaluate Twelve-months Long-Term Safety and Efficacy of GV1001 (1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy(PSP).
- Trial name
- NCT06235775
- Testing
- GV1001 1.12mg
- Where
- 5 sites in South Korea
- Volunteers
- 67 people
- Sponsor
- GemVax & Kael
Parkinson's Disease, Alzheimer's Disease
Biomarkers in Neural Disorders
This study seeks to establish the sensitivity and specificity of what appears to be a unique brainstem biomarker of Parkinson's Disease (PD) - an electrically induced olygosynaptic nasotrigeminal reflex response - in…
- Conditions
- Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor
- Trial name
- NCT02761707
- Testing
- Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Progressive Supranuclear Palsy(PSP)
The Progressive Supranuclear Palsy Clinical Trial Platform
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
- Trial name
- PTP (NCT07173803)
- Testing
- AADvac1, LM11A-31
- Where
- 18 sites in United States
- Volunteers
- 440 people
- Sponsor
- Adam Boxer